InvestorsHub Logo
Followers 1
Posts 191
Boards Moderated 0
Alias Born 05/09/2012

Re: DFRAI post# 541

Monday, 05/15/2017 9:58:02 AM

Monday, May 15, 2017 9:58:02 AM

Post# of 977
This is 2013 news?

In this quarterly release, TRIL stated that the company intend to advance TTI-622, into clinical testing with the filing of an IND submission by the end of 2017.

This may signal TTI-621 may not as effective as the company has hoped.